C07H17/00

METHOD FOR SELECTIVELY PRODUCING GINSENOSIDE RD FROM SAPONINS OF GINSENG THROUGH ENZYMATIC METHOD

The present invention relates to a method for selectively producing ginsenoside Rd, which is originally present in ginseng in a trace amount, from panaxadiol-type saponins of ginseng, and more specifically to a method capable of obtaining a desired target compound, that is, ginsenoside Rd, in high yields, by treating a panaxadiol-type saponin obtained from ginseng, with particular enzymes to structurally convert the saponins.

METHOD FOR SELECTIVELY PRODUCING COMPOUND K AND COMPOUND Y FROM SAPONINS OF GINSENG THROUGH ENZYMATIC METHOD

The present invention relates to a method for selectively producing compound K and compound Y, which are originally present in ginseng in a trace amount, from saponins of ginseng, and more specifically to a method capable of obtaining desired target compounds, that is, compound K and compound Y, in high yields, by treating saponins, obtained from ginseng, with particular enzymes to structurally convert the saponins.

METHOD FOR SELECTIVELY PRODUCING GINSENOSIDE F2, COMPOUND Mc OR COMPOUND O FROM SAPONINS OF GINSENG BY ENZYMATIC PROCESS

The present invention relates to a method for selectively producing ginsenoside F2, compound Mc or compound O, which is originally present in ginseng in a trace amount, from a saponin of ginseng, and more specifically to a method capable of obtaining desired target compounds, that is, ginsenoside F2, compound Mc and compound O, in high yields, by treating saponins, obtained from ginseng, with particular enzymes to structurally convert the saponins.

MACROLIDES AND METHODS OF THEIR PREPARATION AND USE

Provided herein are methods of preparing macrolides by the coupling of an eastern and western half, followed by macrocyclization, to provide macrolides, including both known and novel macrolides. Intermediates in the synthesis of macrolides including the eastern and western halves are also provided. Pharmaceutical compositions and methods of treating infectious diseases and inflammatory conditions using the inventive macrolides are also provided. A general diastereoselective aldol methodology used in the synthesis of the western half is further provided.

MACROLIDES AND METHODS OF THEIR PREPARATION AND USE

Provided herein are methods of preparing macrolides by the coupling of an eastern and western half, followed by macrocyclization, to provide macrolides, including both known and novel macrolides. Intermediates in the synthesis of macrolides including the eastern and western halves are also provided. Pharmaceutical compositions and methods of treating infectious diseases and inflammatory conditions using the inventive macrolides are also provided. A general diastereoselective aldol methodology used in the synthesis of the western half is further provided.

AZIRIDINE SPINOSYN DERIVATIVES AND METHODS OF MAKING
20180291053 · 2018-10-11 · ·

Compositions including derivatives of spinosyns and methods for the production of derivatives of spinosyns are provided. The spinosyn derivatives described herein include those functionalized on the C-5,6 double bond to provide an aziridine ring system. The method produces spinosyn derivatives that exhibit activity towards insects, arachnids, and nematodes and are useful in the agricultural and animal health markets.

AZIRIDINE SPINOSYN DERIVATIVES AND METHODS OF MAKING
20180291053 · 2018-10-11 · ·

Compositions including derivatives of spinosyns and methods for the production of derivatives of spinosyns are provided. The spinosyn derivatives described herein include those functionalized on the C-5,6 double bond to provide an aziridine ring system. The method produces spinosyn derivatives that exhibit activity towards insects, arachnids, and nematodes and are useful in the agricultural and animal health markets.

ASGPR-binding compounds for the degradation of extracellular proteins

Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.

ASGPR-binding compounds for the degradation of extracellular proteins

Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.

ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS

Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.